Chao Guo1, Qijin Pan2, Min Su3, Rong Li4. 1. Department of Pharmacy, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang 537100, Guangxi, PR China. 2. Department of Oncology, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang 537100, Guangxi, PR China. 3. Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541004, PR China. 4. Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541004, PR China. Electronic address: lirong1278@163.com.
Abstract
BACKGROUND: Nasopharyngeal neuroendocrine carcinoma (NNC) refers to a rare and lethal cancer, characterized with high risk of metastases. Here, we report a case of nasopharyngeal neuroendocrine carcinoma with subsequent liver metastases to discuss its clinical immunophenotype and challenges. METHODS: In clinical biochemical assays, hematological determination, immunohistochemical examination, imaging medicine investigations, and therapeutical analysis were subjected to the hospitalized patient, respectively. RESULTS: A group of clinical detectable data highlighted that clinical immunophenotype of nasopharyngeal neuroendocrine carcinoma was identified in immunohistochemical inspection, followed by validation of liver metastases via imaging observations. Subsequent chemotherapy schedule showed disease remission in certain aspect before patient' death. CONCLUSION: Our current clinical data disclose that it is vital to identify nasopharyngeal neuroendocrine carcinoma for main cause of liver metastases with potential risk. Further, early diagnosis and effective pharmacotherapy may improve the survival rate of NNC patient with liver metastases.
BACKGROUND: Nasopharyngeal neuroendocrine carcinoma (NNC) refers to a rare and lethal cancer, characterized with high risk of metastases. Here, we report a case of nasopharyngeal neuroendocrine carcinoma with subsequent liver metastases to discuss its clinical immunophenotype and challenges. METHODS: In clinical biochemical assays, hematological determination, immunohistochemical examination, imaging medicine investigations, and therapeutical analysis were subjected to the hospitalized patient, respectively. RESULTS: A group of clinical detectable data highlighted that clinical immunophenotype of nasopharyngeal neuroendocrine carcinoma was identified in immunohistochemical inspection, followed by validation of liver metastases via imaging observations. Subsequent chemotherapy schedule showed disease remission in certain aspect before patient' death. CONCLUSION: Our current clinical data disclose that it is vital to identify nasopharyngeal neuroendocrine carcinoma for main cause of liver metastases with potential risk. Further, early diagnosis and effective pharmacotherapy may improve the survival rate of NNC patient with liver metastases.